This peptide hormone is well known for its mediative effect in regulating cellular glucose transport in the periphery and has been demonstrated to cross the BBB through insulin transporters [128] to act on insulin receptors which are widespread throughout the brain, localized on neurons, astrocytes, and microglia [129,130,131]
Request comprehensive metabolic panels every three to six months during treatment and every one to three months during and after tapering
The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1
At 20mg/mL, doses from 2mg to 12mg all fit in one draw, making it the most versatile concentration for a full dose escalation schedule
GoodRX has a tool on its site for seeing how much your medication typically costs with your specific type of insurance
Combining with DPP-4 inhibitors is generally not recommended, as both drug classes work on the incretin system Adding basal insulin for those with more significant hyperglycaemia, which can be used alongside GLP-1 medications (with careful monitoring for hypoglycaemia) Switching to insulin therapy entirely may be necessary for those with advanced beta cell failure For weight management , when GLP-1 medications don't produce adequate weight loss, alternatives include: Orlistat , a lipase inhibitor that reduces fat absorption, though weight loss is typically modest (2-3 kg on average) Naltrexone-bupropion (Mysimba), which works on appetite centres through different pathways
